| pubmed-article:12766731 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12766731 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:12766731 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:12766731 | lifeskim:mentions | umls-concept:C1956346 | lld:lifeskim |
| pubmed-article:12766731 | lifeskim:mentions | umls-concept:C0878544 | lld:lifeskim |
| pubmed-article:12766731 | lifeskim:mentions | umls-concept:C0034595 | lld:lifeskim |
| pubmed-article:12766731 | lifeskim:mentions | umls-concept:C0001721 | lld:lifeskim |
| pubmed-article:12766731 | lifeskim:mentions | umls-concept:C0039593 | lld:lifeskim |
| pubmed-article:12766731 | lifeskim:mentions | umls-concept:C0679199 | lld:lifeskim |
| pubmed-article:12766731 | lifeskim:mentions | umls-concept:C0750502 | lld:lifeskim |
| pubmed-article:12766731 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:12766731 | pubmed:dateCreated | 2003-5-26 | lld:pubmed |
| pubmed-article:12766731 | pubmed:abstractText | Ischemic heart failure is a significant source of morbidity and mortality, yet it has an unclear treatment strategy. The assessment of viable myocardium by nuclear imaging studies has shown promise in predicting improvements in ejection fraction and symptoms. However, the relationship of viability to long-term mortality has not been fully established. | lld:pubmed |
| pubmed-article:12766731 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12766731 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12766731 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:12766731 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12766731 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12766731 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12766731 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12766731 | pubmed:month | May | lld:pubmed |
| pubmed-article:12766731 | pubmed:issn | 1097-6744 | lld:pubmed |
| pubmed-article:12766731 | pubmed:author | pubmed-author:ShawLinda KLK | lld:pubmed |
| pubmed-article:12766731 | pubmed:author | pubmed-author:O'ConnorChris... | lld:pubmed |
| pubmed-article:12766731 | pubmed:author | pubmed-author:WhellanDavid... | lld:pubmed |
| pubmed-article:12766731 | pubmed:author | pubmed-author:VelazquezEric... | lld:pubmed |
| pubmed-article:12766731 | pubmed:author | pubmed-author:Borges-NetoSa... | lld:pubmed |
| pubmed-article:12766731 | pubmed:author | pubmed-author:BourqueJamies... | lld:pubmed |
| pubmed-article:12766731 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:12766731 | pubmed:volume | 145 | lld:pubmed |
| pubmed-article:12766731 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12766731 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12766731 | pubmed:pagination | 758-67 | lld:pubmed |
| pubmed-article:12766731 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:12766731 | pubmed:meshHeading | pubmed-meshheading:12766731... | lld:pubmed |
| pubmed-article:12766731 | pubmed:meshHeading | pubmed-meshheading:12766731... | lld:pubmed |
| pubmed-article:12766731 | pubmed:meshHeading | pubmed-meshheading:12766731... | lld:pubmed |
| pubmed-article:12766731 | pubmed:meshHeading | pubmed-meshheading:12766731... | lld:pubmed |
| pubmed-article:12766731 | pubmed:meshHeading | pubmed-meshheading:12766731... | lld:pubmed |
| pubmed-article:12766731 | pubmed:meshHeading | pubmed-meshheading:12766731... | lld:pubmed |
| pubmed-article:12766731 | pubmed:meshHeading | pubmed-meshheading:12766731... | lld:pubmed |
| pubmed-article:12766731 | pubmed:meshHeading | pubmed-meshheading:12766731... | lld:pubmed |
| pubmed-article:12766731 | pubmed:meshHeading | pubmed-meshheading:12766731... | lld:pubmed |
| pubmed-article:12766731 | pubmed:meshHeading | pubmed-meshheading:12766731... | lld:pubmed |
| pubmed-article:12766731 | pubmed:meshHeading | pubmed-meshheading:12766731... | lld:pubmed |
| pubmed-article:12766731 | pubmed:meshHeading | pubmed-meshheading:12766731... | lld:pubmed |
| pubmed-article:12766731 | pubmed:meshHeading | pubmed-meshheading:12766731... | lld:pubmed |
| pubmed-article:12766731 | pubmed:meshHeading | pubmed-meshheading:12766731... | lld:pubmed |
| pubmed-article:12766731 | pubmed:meshHeading | pubmed-meshheading:12766731... | lld:pubmed |
| pubmed-article:12766731 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12766731 | pubmed:articleTitle | Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? | lld:pubmed |
| pubmed-article:12766731 | pubmed:affiliation | Division of Cardiology, Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA. bourq002@mc.duke.edu | lld:pubmed |
| pubmed-article:12766731 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12766731 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:12766731 | pubmed:publicationType | Meta-Analysis | lld:pubmed |
